Hypothetical case - For market research purposes only
UNITED BY CANCER
About UsOur TreatmentsOur Science
Our StoryEventsResources
Profile
Search
You are about to enter Our Science, which contains information concerning our Research & Development activities as well as other information produced by our Medical Affairs function.
You are about to enter Our Treatments, which contains information promoting the use of our approved medicines.

Belantamab Mafodotin-Blmf Mechanism Of Action

BLENREP is subject to a BOXED WARNING. Please view full Prescribing Information including BOXED WARNING HERE.

Belantamab mafodotin-blmf (BLENREP) is approved in the US for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.1 

Any other intended use of belantamab mafoditin-blmf reviewed is investigational. This video is not intended to imply clinical safety or efficacy of the compound or that it has or will receive additional regulatory approvals. 

Information about GSK-sponsored clinical trials is available at www.ClinicalTrials.gov.

  1. BLENREP. Prescribing information. GlaxoSmithKline; 2020.